Identification of the ligand-binding domain of human vascular-endothelial-growth-factor receptor Flt-1

Li Ma; Xiaoning Wang; Zhiqing Zhang; Xiaoming Zhou; Aijun Chen; Lihong Yao

doi:10.1042/ba20010043

Identification of the ligand-binding domain of human vascular-endothelial-growth-factor receptor Flt-1

Biotechnology and Applied Biochemistry ◽

10.1042/ba20010043 ◽

2001 ◽

Vol 34 (3) ◽

pp. 199 ◽

Cited By ~ 5

Author(s):

Li Ma ◽

Xiaoning Wang ◽

Zhiqing Zhang ◽

Xiaoming Zhou ◽

Aijun Chen ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Ligand Binding ◽

Growth Factor Receptor ◽

Binding Domain ◽

Ligand Binding Domain ◽

Vascular Endothelial ◽

Endothelial Growth Factor

Download Full-text

Molecularly Imprinted Nanocavities Capable of Ligand-Binding Domain and Size/Shape Recognition for Selective Discrimination of Vascular Endothelial Growth Factor Isoforms

ACS Sensors ◽

10.1021/acssensors.7b00622 ◽

2018 ◽

Vol 3 (3) ◽

pp. 580-586 ◽

Cited By ~ 9

Author(s):

Yuri Kamon ◽

Toshifumi Takeuchi

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Ligand Binding ◽

Shape Recognition ◽

Binding Domain ◽

Ligand Binding Domain ◽

Vascular Endothelial ◽

Molecularly Imprinted ◽

Endothelial Growth Factor

Download Full-text

Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding

Oncotarget ◽

10.18632/oncotarget.12108 ◽

2016 ◽

Vol 7 (45) ◽

pp. 72868-72885 ◽

Cited By ~ 9

Author(s):

Grazia Graziani ◽

Federica Ruffini ◽

Lucio Tentori ◽

Manuel Scimeca ◽

Annalisa S. Dorio ◽

...

Keyword(s):

Monoclonal Antibody ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Antitumor Activity ◽

Ligand Binding ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endothelial Growth Factor

Download Full-text

Mapping of the Sites for Ligand Binding and Receptor Dimerization at the Extracellular Domain of the Vascular Endothelial Growth Factor Receptor FLT-1

Journal of Biological Chemistry ◽

10.1074/jbc.272.16.10382 ◽

1997 ◽

Vol 272 (16) ◽

pp. 10382-10388 ◽

Cited By ~ 139

Author(s):

Bernhard Barleon ◽

Frank Totzke ◽

Christel Herzog ◽

Stephen Blanke ◽

Elisabeth Kremmer ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Ligand Binding ◽

Growth Factor Receptor ◽

Extracellular Domain ◽

Vascular Endothelial ◽

Receptor Dimerization ◽

Endothelial Growth Factor

Download Full-text

Role of the Heparin Binding Domain in the Clearance and Localization of Vascular Endothelial Growth Factor

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(97)88004-7 ◽

1998 ◽

Vol 31 (2) ◽

pp. 461A ◽

Cited By ~ 1

Author(s):

P Kimson

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Binding Domain ◽

Vascular Endothelial ◽

Heparin Binding ◽

Heparin Binding Domain ◽

Endothelial Growth Factor

Download Full-text

Fortgeschrittenes medulläres Schilddrüsenkarzinom: Vandetanib verbessert das progressionsfreie Überleben

Onkologische Welt ◽

10.1055/s-0038-1631032 ◽

2012 ◽

Vol 03 (02) ◽

pp. 93-92

Author(s):

Alexander Kretzschmar

Keyword(s):

Vascular Endothelial Growth Factor ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Phase Iii ◽

Vascular Endothelial ◽

Medulläres Schilddrüsenkarzinom ◽

Epidermal Growth ◽

Endothelial Growth Factor

Vandetanib ist ein oraler Hemmer des RET-Kinase-, VEGF (Vascular Endothelial Growth Factor Receptor)- und EGFR (Epidermal Growth Factor Receptor)-Signalwegs. In einer zulassungsrelevanten, randomisierten, doppelblinden, placebokontrollierten Phase- III-Studie verlängerte der Tyrosinkinasehemmer das progressionsfreie Überleben (PFS) signifikant länger als Placebo.

Download Full-text

Expression des „Epidermal Growth-Factor Receptor“ (EGFR) und des „Vascular Endothelial Growth Factor“ (VEGF) bei Lymphangioleiomyomatose (LAM)

Pneumologie ◽

10.1055/s-2006-934022 ◽

2006 ◽

Vol 60 (S 1) ◽

Author(s):

H Watz ◽

K Engels ◽

M Amthor ◽

D Kirsten ◽

H Magnussen

Keyword(s):

Vascular Endothelial Growth Factor ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Epidermal Growth ◽

Endothelial Growth Factor

Download Full-text

Faculty Opinions recommendation of Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1163678.625451 ◽

2009 ◽

Author(s):

David Bates

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Lymphatic Vessel ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endogenous Inhibitor ◽

Vessel Growth ◽

Alternatively Spliced ◽

Endothelial Growth Factor

Download Full-text

Faculty Opinions recommendation of Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.11744956.12828054 ◽

2011 ◽

Author(s):

Asma Nusrat

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Receptor Antagonism ◽

Endothelial Growth Factor ◽

Α2β1 Integrin

Download Full-text

Faculty Opinions recommendation of Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.11744956.13740054 ◽

2011 ◽

Author(s):

Richard L Stevens

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Receptor Antagonism ◽

Endothelial Growth Factor ◽

Α2β1 Integrin

Download Full-text

Faculty Opinions recommendation of 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697854.793153053 ◽

2012 ◽

Author(s):

Hendrik van Poppel ◽

Yuri Tolkach

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Renal Cell Cancer ◽

Renal Cell ◽

Cell Cancer ◽

Neoadjuvant Treatment ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Endothelial Growth Factor ◽

Receptor Inhibitor

Download Full-text